Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-10-29
2000-11-14
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3144
Patent
active
061470953
ABSTRACT:
The present invention relates to a novel method for improving the pharmacokinetics of tipranavir, comprising administering to a human in need of such treatment a combination of a therapeutically effective amount of tipranavir or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of ritonavir or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 5843990 (1998-12-01), Baker
patent: 5932570 (1999-08-01), Rodgers et al.
A Cato III, J Cavanaugh, H Shi, A Hsu, J Leonard, R Granneman,"The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin, " Clinical Pharmacology & Therapeutics, Apr. 1998, vol. 63, No. 4:414-421.
A Cato III, J Qian, A Hsu, B Levy, J Leonard, R Granneman, "Multidose Pharmacokinetics of Ritonavir and Zidovudine in Human Immunodeficiency Virus-Infected Patients," Antimicrobial Agents an Chemotherapy, Jul. 1998, vol. 42:1788-1793.
VK Chaudhary, T Mizukami, TR Fuerst, DJ FitzGerald, B Moss, I Pastan, EA Berger, "Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein," Nature, 1988, 335:369-372.
KT Chong, PJ Pagano, "In Vitro Combination of PNU-140690, A Human Immunodeficiency Virus Type 1 Protease Inhibitor, with Ritonavir against Ritonavir-Sensitive and -Resistant Clinical Isolates," Antimicrobial Agents and Chemotherapy, Nov. 1997, vol. 41, No. 11:2367-2373.
PL Darke, C-T Leu, LJ Davis, JC Heimbach, RE Diehl, WS Hill, RAF Dixon, IS Sigal,"Human Immunodeficiency Virus Protease," J. Biol. Chem., 1989, 264:2307-2312.
PL Darke, RF Nutt, SF Brady, VM Garsky, TM Ciccarone, C-T Leu, PK Lumma, RM Freidinger, DF Veber, IS Sigal, "HIV-1 Protease Specificity of Peptide Cleavage is Sufficient," Biochem. Biophys. Res. Communs., 1988, 156:297-303.
KC Deen, JS McDougal, R Inacker, G Folena-Wasserman, J Arthos, J Rosenberg, PJ Maddon, R Axel, RW Sweet, "A Soluble form of CD4 (T4) protein inhibits AIDS virus infection," Nature, 1998, 331:82-84.
P Duesberg, "Human Immunodeficiency virus and acquired immunodeficiency syndrome: Correlation but not causation," Proc. Natl. Acad. Sci., USA, 1989 86:755-764.
RA Fisher, JM Bertonis, W Meier, VA Johnson, DS Costopoulos, T Liu, R Tizard, BD Walker, MS Hirsch, RT Schooley, RA Flavell, "HIV infection is Blocked in vitro by recombinant soluble CD4," Nature, 1988, 331:76-78.
C-Z Giam, I Borsos, "In Vivo and in Vitro Autoprocessing of Human Immunodeficiency Virus Protease Expressed in Escherichia coli," J. Biol. Chem., 1988, 263:14617-14620.
J Hansen, S Billich, T Schulze, S Sukrow, K Moelling, "Partial purification and substrate analysis of bacterially expressed HIV protease by means of monoclonal antibody," EMBO J., 1988 7:1785-1791.
A Hsu, GR Granneman, G Cao, L Carothers, R El-Shourbagy, P Baroldi, K Erdman, F Brown, E Sun, JM Leonard, "Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir," Clinical Pharmacology & Therapeutics, Apr. 1998, vol. 63, No.4:453-464.
RE Hussey, NE Richardson, M Kowalski, NR Brown, H-C Chang, RF Siliciano, T Dorfman, B Walker, J Sodroski, EL Reinherz, "A Soluble CD4 protein selectively inhibits HIV replication and syncytium formation," Nature, 1988, 331:78-81.
I Katoh, T Yasunaga, Y Ikawa, Y Yoshinaka, "Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor," Nature, 1987 329:654-656.
NE Kohl, EA Emini, WA Schleif, LJ Davis JC Heimbach, RAF Dixon, EM Scolnick, IS Sigal, "Active human immunodeficiency virus protease is required for viral infectivity," Proc. Natl. Acad. Sci., USA, 1988 85:4686-4690.
JA Martin, "Recent advances in the design of HIV proteinase inhibitors," Antiviral Research, 1992, 17:265-278.
TJ McQuade, AG Tomasselli, L Liu, V Karacostas, B Moss, TK Sawyer, RL Heinrikson, WG Tarpley, "A Synthetic HIV-1 Protease Inhibitor with Antiviral Activity Arrests HIV-Like Particle Maturation," Science, 1990, 247:454-456.
M Miller, M Jaskolski, JK Mohana Rao, J Leis, A Wlodawer, "Crystal structure of a retroviral protease proves relationship to aspartic protease family," Nature, 1989, 337:576-579.
MA Muesing, DH Smith, CD Cabradilla, CV Benton, LA Lasky, DJ Capon, "Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus," Nature, 1985, 313:450-458.
MA Navia, PMD Fitzgerald, BM McKeever, C-T Leu, JC Heimbach, WK Herber, IS Sigal, PL Darke, JP Springer, "Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1," Nature, 1989, 337:615-620.
RF Nutt, SF Brady, PL Darke, TM Ciccarone, CD Colton, EM Nutt, JA Rodkey, CD Bennett, LH Waxman, Is.
Sigal, PS Anderson, Df Veber, "Chemical synthesis and enzymatic activity opf a 99-residue peptide with a sequence proposed for the human immunodeficiency virus protease," Proc. Natl. Acad. Sci., USA, 1988, 85:7129-7133.
D Ouellet, A Hsu, J Qian, CS Locke, CJ Eason, JH Cavanaugh, JM Leonard, GR Granneman, "Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in heathy female volunteers," J. Clin Pharmacology, 1998, 46:111-116.
LH Pearl, WR Taylor, "A structural model for the retroviral proteases," Nature, 1987, 329:351-354.
L Ratner, W Haseltine, R Patarca, KJ Livak, B Starcich, SF Josephs, ER Doran, JA Rafalski, EA Whitehorn, K Baumeister, L Ivanoff, SR Petteway Jr., ML Pearson, JA Lautenberger, TS Papas, J Ghrayeb, NT Chang, RC Gallo, F Wong-Staal, "Complete nucleotide sequence of the AIDS virus, HTLV-III," Nature, 1985, 313:277-284.
R Sanchez-Pescador, MD Power, PJ Barr, KS Steimer, MM Stempein, SL Brown-Shimer, WW Gee, A Renard, A Randolph, JA Levy, D Dina, PA Luciw, "Nucleotide Sequence and Expression of an AIDS-Associated Retrovirus (ARV-2)," Science, 1985, 227:484-492.
J Schneider, SB Kent, SBH Kent, "Enzymatic Activity of a Synthetic 99 Residue Protein Corresponding to the Putative HIV-1 Protease," Cell, 1988, 54:363-368.
S Seelmeier, H Schmidt, V Turk, K von der Helm, "Human Immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A," Proc. Natl. Acad. Sci., USA, 1988, 85:6612-6616.
DH Smith, RA Byrn, SA Marsters, T Gregory, JE Groopman, DJ Capon, "Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen," Science, 1987, 238:1704-1707.
MA Till, V Ghetie, T Gregory, EJ Patzer, JP Porter, JW Uhr, DJ Capon, ES Vitetta, "HIV-Infected Cells Are Killed by rCD4-Ricin A Chain," Science, 1988, 242:1166-1168.
K von der Helm,"Cleavage of Rous sacorma viral polypeptide precursor into internal structural proteins in vitro involves viral protein p15," Proc. Natl. Acad. Sci., USA, 1977, 74:911-915.
S Wain-Hobson, P Sonigo, O Danos, S Cole, M Alizon, "Nucleotide Sequence of the AIDS Virus, LAV," Cell, 1985, 40:9-17.
Y Yoshinaka, I Katoh, TD Copeland, GW Smythers, S Oroszlan, "Bovine Leukemia Virus Protease: Purification, Chemical Analysis, and In Vitro Processing of gag Precursor Polyproteins," J. Virol., 1986, 57:826-832.
Y Yoshinaka, I Katoh, TD Copeland, S Oroszlan "Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon," Proc. Natl. Acad. Sci., USA, 1985, 82:1618-1622.
Y Yoshinaka, I Katoh, TD Copeland, S Oroszlan "Translational Readthrough of an Amber Termination Codon During Synthesis of Feline Leukemia Virus Protease," J. Virol., 1985, 55:870-873.
Baldwin John R.
Borin Marie T.
Ferry James J.
Henley III Raymond
Pharmacia & Upjohn Company
Yang Lucy X.
LandOfFree
Method for improving the pharmacokinetics of tipranavir does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for improving the pharmacokinetics of tipranavir, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for improving the pharmacokinetics of tipranavir will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2065776